Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group

Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, Børge G. Nordestgaard, Carl Edward Orringer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

Original languageEnglish (US)
JournalJournal of Clinical Lipidology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lipoprotein(a)
Biomarkers
Lipids
Aortic Valve Stenosis
Primary Prevention
Secondary Prevention
Cardiovascular Diseases
Stroke
Myocardial Infarction
Population
Therapeutics

Keywords

  • Atherosclerotic cardiovascular disease
  • Biomarker
  • Calcific valvular aortic disease
  • Cardiovascular risk
  • Coronary heart disease
  • Cutpoints
  • Lifestyle
  • Lipoprotein (a)
  • Lp(a)
  • Myocardial infarction
  • Primary prevention
  • Scientific statement
  • Secondary prevention
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Use of lipoprotein(a) in clinical practice : A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group. / Wilson, Don P.; Jacobson, Terry A.; Jones, Peter H.; Koschinsky, Marlys L.; McNeal, Catherine J.; Nordestgaard, Børge G.; Orringer, Carl Edward.

In: Journal of Clinical Lipidology, 01.01.2019.

Research output: Contribution to journalArticle

@article{292bc3591d17437f805ff274b6c70466,
title = "Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group",
abstract = "Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20{\%} of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.",
keywords = "Atherosclerotic cardiovascular disease, Biomarker, Calcific valvular aortic disease, Cardiovascular risk, Coronary heart disease, Cutpoints, Lifestyle, Lipoprotein (a), Lp(a), Myocardial infarction, Primary prevention, Scientific statement, Secondary prevention, Stroke, Treatment",
author = "Wilson, {Don P.} and Jacobson, {Terry A.} and Jones, {Peter H.} and Koschinsky, {Marlys L.} and McNeal, {Catherine J.} and Nordestgaard, {B{\o}rge G.} and Orringer, {Carl Edward}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jacl.2019.04.010",
language = "English (US)",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Use of lipoprotein(a) in clinical practice

T2 - A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group

AU - Wilson, Don P.

AU - Jacobson, Terry A.

AU - Jones, Peter H.

AU - Koschinsky, Marlys L.

AU - McNeal, Catherine J.

AU - Nordestgaard, Børge G.

AU - Orringer, Carl Edward

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

AB - Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

KW - Atherosclerotic cardiovascular disease

KW - Biomarker

KW - Calcific valvular aortic disease

KW - Cardiovascular risk

KW - Coronary heart disease

KW - Cutpoints

KW - Lifestyle

KW - Lipoprotein (a)

KW - Lp(a)

KW - Myocardial infarction

KW - Primary prevention

KW - Scientific statement

KW - Secondary prevention

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85066092438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066092438&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2019.04.010

DO - 10.1016/j.jacl.2019.04.010

M3 - Article

C2 - 31147269

AN - SCOPUS:85066092438

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

ER -